Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) EBITDA: 2023-2024

Historic EBITDA for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to -$156.8 million.

  • Zenas BioPharma's EBITDA fell 33.16% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.0 million, marking a year-over-year decrease of 47.26%. This contributed to the annual value of -$156.8 million for FY2024, which is 323.34% down from last year.
  • As of FY2024, Zenas BioPharma's EBITDA stood at -$156.8 million, which was down 323.34% from -$37.0 million recorded in FY2023.
  • Over the past 5 years, Zenas BioPharma's EBITDA peaked at -$37.0 million during FY2023, and registered a low of -$156.8 million during FY2024.
  • Its 2-year average for EBITDA is -$96.9 million, with a median of -$96.9 million in 2023.
  • Data for Zenas BioPharma's EBITDA shows a maximum YoY tumbled of 323.34% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's EBITDA (Yearly) stood at -$37.0 million in 2023, then crashed by 323.34% to -$156.8 million in 2024.